Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc.

What Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc. does

The Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc. is a non-profit research corporation and a research centre of the University of Saskatchewan, headquartered in Saskatoon. It operates the Saskatchewan Cyclotron Facility — a 24 MeV cyclotron with adjacent laboratories licensed for safe handling of nuclear substances — and serves as Saskatchewan's sole producer of FDG (fluorodeoxyglucose) radiopharmaceutical, supplying regional hospitals for PET/CT cancer diagnostic imaging (over 2,400 patients annually). It also produces radiopharmaceuticals for research applications and provides radiochemistry and nuclear imaging research capabilities.

The Centre generates revenue through a portfolio of streams: direct FDG sales to hospitals, usage-based facility user fees for academic and industry access (restructured effective April 1, 2026 with 20-30% of capacity reserved for USask discovery research at nominal cost), government grants supporting research and operations, industrial isotope contracts, technology licensing, and philanthropic donations. Its go-to-market is direct, with no traditional resale channels: direct supply to Saskatchewan hospitals, direct facility access for USask researchers, and contract-based industrial access.

The Centre plays an orchestrating role in Canada's nuclear ecosystem — co-leading the Canadian Neutron Initiative (2016-2022) and incubating Neutrons Canada as an independent pan-Canadian non-profit — and engages in public-policy work on Small Modular Reactors in partnership with SaskPower and on nuclear policy with the Johnson Shoyama Graduate School of Public Policy. Its operations are governed by a Board of Directors including the USask Vice-President Research, with leadership under Executive Director Dr. Jeter Hall (effective July 2, 2025).

Name

Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc.

Legal name

The Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc.

Website

https://fedorukcentre.ca

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Saskatchewan non-profit research centre operating the province's sole 24 MeV cyclotron facility, producing FDG radiopharmaceuticals for PET/CT cancer diagnostics, funding nuclear research, and consulting on nuclear technologies and policy.

Ownership category

akta.pro rank

Product category

Nuclear Research and Radiopharmaceutical Production

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industry

Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)

Keywords

• Nuclear research services
• Radiopharmaceutical production
• Cyclotron facility access
• PET imaging isotopes
• Nuclear innovation grants

Headquarters

HQ city

Saskatoon

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Radiopharmaceutical Sales: Production and sale of FDG (fluorodeoxyglucose) to regional hospitals for PET/CT diagnostic imaging in cancer diagnosis.
2. Facility User Fees: Fees charged for academic and industry access to cyclotron facility, laboratory workstations, and equipment. Effective April 2026, restructured with significant free access for USask discovery research.
3. Government Grants: Funding from government sources to support research programs, neutron imaging initiatives, and facility operations.
4. Industrial Contracts: Revenue from industrial contracts and isotope sales to external commercial entities.
5. Licensing Revenue: Revenue from licensed inventions or technologies developed through research programs.
6. Philanthropic Donations: Support through donations to advance nuclear innovation research and facility capabilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Fedoruk Centre produces and supplies FDG (fluorodeoxyglucose) radiopharmaceuticals to Saskatchewan hospitals for PET/CT cancer diagnostic imaging, and operates a 24 MeV Saskatchewan Cyclotron Facility providing radiopharmaceutical production and laboratory access to academic and industry researchers. It supplements these operational services with research funding grants in life sciences and nuclear technologies and impartial consulting on nuclear energy policy and public engagement.

Product overview

The Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc. operates as a research centre of the University of Saskatchewan, offering a portfolio of nuclear medicine and research services rather than a traditional product platform. The core offering centers on the Saskatchewan Cyclotron Facility, which houses a 24 MeV cyclotron for producing FDG (fluorodeoxyglucose) radiopharmaceuticals for PET/CT scans used in cancer diagnosis—making the Centre Saskatchewan's sole FDG producer. Adjacent to clinical production, the facility produces radiopharmaceuticals for research applications. The Centre supplements its operational services with research funding grants for scientists in life sciences, radiochemistry, and nuclear technologies, plus consulting services for public engagement on nuclear technologies. These offerings work together to advance medical health and environmental sustainability through nuclear science.

Differentiator

Problem solved

Functional benefit

Products and services

• FDG (Fluorodeoxyglucose) Radiopharmaceutical Production Production and supply of FDG radiopharmaceuticals to regional hospitals in Saskatchewan for use in PET/CT scans for cancer diagnosis. The Fedoruk Centre is Saskatchewan's sole producer, supporting over 2,400 patient scans annually.
• Saskatchewan Cyclotron Facility Services Operation of a 24 MeV cyclotron and adjacent laboratories providing access for academic and industry users to produce radiopharmaceuticals and conduct nuclear imaging research. Includes restructured free discovery research access for USask users effective April 2026.
• Research-Grade Radiopharmaceuticals Production of radiopharmaceuticals for research applications in life sciences and nuclear medicine, in addition to clinical FDG supply.
• Research Funding and Grants Grants awarded to scientists and researchers for projects aligned with the Centre's purpose in life sciences, radiochemistry, nuclear technologies, and public engagement with the nuclear industry.
• Nuclear Technology Consulting Services Impartial information and consultation services promoting respectful public conversations about nuclear technologies and supporting Saskatchewan's leadership in nuclear initiatives within and beyond Canada.

Quantifiable outcome

• 2400+ patients served annually with PET/CT scans using locally-produced FDG
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• University of SaskatchewancoreStrategic or Co-development PartnerThe Fedoruk Centre is a research centre of the University of Saskatchewan, operating as an independent non-profit corporation while maintaining close institutional ties. The partnership enables academic leadership for nuclear research and education programs, attracts faculty members, and develops highly qualified personnel. Vice-President Research Dr. Baljit Singh serves as a Board Director.
• Neutrons CanadamajorStrategic or Co-development PartnerFrom January 2023, the Fedoruk Centre provided 23 months of interim management services supporting Neutrons Canada's transition towards independent operation. Helped secure 16 organizational Members and established sound operating practices for the Board of Directors. Neutrons Canada was established as a pan-Canadian not-for-profit corporation to rebuild Canada's global presence in materials research with neutron beams.
• Canadian Neutron Initiative (CNI) Working GroupmajorStrategic or Co-development PartnerFrom 2016 to 2022, the CNI working group was co-led by VPs of Research from University of Saskatchewan (Karen Chad, then Baljit Singh) and McMaster University (Karen Mossman). Work culminated in establishing Neutrons Canada in November 2022, setting the stage for rebuilding Canada's global presence in materials research with neutron beams.
• Saskatchewan InstitutionscoreStrategic or Co-development PartnerPartnerships with Saskatchewan institutions (University of Saskatchewan, University of Regina) to strengthen academic leadership for nuclear research and education programs. These partnerships help attract new faculty members who develop highly qualified people in the sector.
• SaskPowerminorStrategic or Co-development PartnerFedoruk Centre supports Saskatchewan's nuclear initiatives including Small Modular Reactor (SMR) planning. Executive Director provides expertise and commentary on nuclear energy discussions and policy development with SaskPower's regional evaluation process for nuclear power.
• McMaster UniversitymajorStrategic or Co-development PartnerCo-led the Canadian Neutron Initiative (CNI) working group from 2016-2022 alongside University of Saskatchewan. VP Research Karen Mossman from McMaster co-led efforts that culminated in establishing Neutrons Canada.
• Johnson Shoyama Graduate School of Public PolicyminorStrategic or Co-development PartnerPartnership on nuclear energy policy research and public engagement. Published impact report on the collaboration (March 2023) addressing Saskatchewan and nuclear option policy briefs.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• TRIUMF: Canada's particle accelerator centre at UBC, producing medical isotopes and conducting nuclear physics research. Most comparable to Fedoruk Centre as a Canadian non-profit accelerator facility with radiopharmaceutical production and academic research missions.
• McMaster Nuclear Reactor (MNR): University research reactor at McMaster University producing medical isotopes including I-125 and Mo-99. Comparable academic-affiliated isotope production facility, and Fedoruk Centre co-led the CNI alongside McMaster's VP Research.

Broad incumbents

• Canadian Nuclear Laboratories (CNL): Canada's premier nuclear science and technology organization operating Chalk River Laboratories. Comparable as a federally affiliated nuclear R&D hub, though broader in scope than Fedoruk Centre's regional radiopharmaceutical focus.
• Nordion: Leading supplier of medical isotopes and sterilization services headquartered in Canada. Comparable as a Canadian medical isotope supplier, though at commercial scale well beyond Fedoruk's regional cyclotron operations.
• Lantheus Holdings: Radiopharmaceutical company with FDG and specialty PET agents. Comparable in FDG production for cancer imaging, but as a publicly traded commercial manufacturer rather than a research centre.
• Curium Pharma: Global nuclear medicine company supplying SPECT/PET radiopharmaceuticals. Comparable product line but operates commercially at scale across multiple geographies, contrasting with Fedoruk's regional non-profit model.
• BWXT Medical: Manufacturer of medical isotopes and radiopharmaceuticals with operations in Canada. Comparable as an established commercial radiopharmaceutical producer, but at much greater scale and with private ownership.

Others

• Bruce Power: Ontario-based nuclear power generator and isotope producer. Connected to Fedoruk Centre through Canada's broader nuclear ecosystem and isotope supply chain, though not a direct radiopharmaceutical competitor.

Emerging players

• ITM Isotope Technologies Munich: Producer of medical radioisotopes and radiopharmaceuticals with growing global manufacturing footprint. Comparable radiopharmaceutical production focus with emerging commercial scale.

Regional players

• Saskatchewan Research Council (SRC): Saskatchewan's provincial R&C organization with involvement in nuclear and SMR initiatives. Operates in the same province with overlapping nuclear energy interests but a much broader industrial mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sylvia-fedoruk-canadian-centre-for-nuclear-innovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc.